

TABLE S4. Treatment-Related AEs Occurring in ≥1% of Subjects by Treatment Cycle

	Occurring Over Entire Cycle			Occurring up to 12 weeks after injection		
	Treatment 1 (n = 2380)	Treatment 2 (n = 882)	Treatment 3 (n = 568)	Treatment 1 (n = 2380)	Treatment 2 (n = 882)	Treatment 3 (n = 568)
Subjects with ≥1 treatment-emergent AE	400 (16.8)	86 (9.8)	40 (7.0)	399 (16.8)	86 (9.8)	40 (7.0)
Headache	102 (4.3)	13 (1.5)	12 (2.1)	102 (4.3)	13 (1.5)	12 (2.1)
Injection site pain	81 (3.4)	18 (2.0)	7 (1.2)	81 (3.4)	18 (2.0)	7 (1.2)
Injection site erythema	64 (2.7)	22 (2.5)	8 (1.4)	64 (2.7)	22 (2.5)	8 (1.4)
Injection site edema	56 (2.4)	21 (2.4)	9 (1.6)	56 (2.4)	21 (2.4)	9 (1.6)
Erythema	47 (2.0)	3 (0.3)	1 (0.2)	47 (2.0)	3 (0.3)	1 (0.2)

Edema	43 (1.8)	4 (0.5)	–	43 (1.8)	4 (0.5)	–
Eyelid ptosis	23 (1.0)	7 (0.8)	4 (0.7)	23 (1.0)	7 (0.8)	4 (0.7)

AE, adverse event.

